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Charles Mullighan,1 Effie Petersdorf,2 Stella M. Davies,3 John DiPersio4Crick, Watson, and colleagues revealed the genetic code in 1953, and since that time, remarkable progress
has beenmade in understanding what makes each of us whowe are. Identification of single genes important in
disease, and the development of a mechanistic understanding of genetic elements that regulate gene function,
have cast light on the pathophysiology of many heritable and acquired disorders. In 1990, the human genome
project commenced, with the goal of sequencing the entire human genome, and a ‘‘first draft’’ was published
with astonishing speed in 2001. The first draft, although an extraordinary achievement, reported essentially
an imaginary haploid mix of alleles rather than a true diploid genome. In the years since 2001, technology has
further improved, and efforts have been focused on filling in the gaps in the initial genome and starting the
huge task of looking at normal variation in the human genome. This work is the beginning of understanding
human genetics in the context of the structure of the genome as a complete entity, and as more than simply
the sum of a series of genes. We present 3 studies in this review that apply genomic approaches to leukemia
and to transplantation to improve and extend therapies.
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ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Genome-Wide Profiling of ALL Samples
Obtained at Diagnosis
Multiple studies have used microarray-based pro-
filing to identify submicroscopic genetic alterations in
ALL, predominantly in children. These studies have
made several important observations. In contrast to
many solid tumors, ALL is characterized by a relatively
low number of genetic alterations—approximately 6 to
8 lesions per case [1,2]. These alterations commonly
target genes and pathways with key roles in
leukemogenesis. These include mutations targeting
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6/j.bbmt.2010.10.026(eg, PAX5, IKZF1, and EBF1), cell cycle regulators,
and tumor suppressor genes (CDKN2A, CDKN2B,
RB1, and PTEN), lymphoid signaling genes (CD200,
BTLA, and BLNK), and drug-response genes (eg, the
glucocorticoid receptor gene NR3C1). Genes regulating
B lymphoid development are mutated in the majority of
B-progenitor ALL cases, most commonly deletions,
sequence mutations, or translocations of PAX5 [1], dele-
tion (and less commonly, sequencemutation) of IKZF1
(IKAROS), and the IKAROS family members IKZF2
(HELIOS) and IKZF3 (AIOLOS), and deletion of
EBF1. These mutations result in loss of function in
vitro, and accelerate the onset of ALL in murine
models [3-5].Genomic Profiling of High-Risk ALL—ACentral
Role of IKZF1
The pattern of genetic alterations in ALL is
strongly associated with disease subtype. MLL-
rearranged ALL cases harbor fewer than 1 copy
number alteration per case, suggesting few deletions
are required to induce leukemia [1,6]. In contrast,
ETV6-RUNX1 and BCR-ABL1 (Ph1) ALL cases
harbor multiple distinct copy number alterations [1].
Deletion of IKZF1 (IKAROS) is a hallmark of Ph1
de novo ALL and chronic myeloid leukemia (CML)
at progression to lymphoid blast crisis [2,7].
IKAROS is a zinc-finger transcription factor with
complex actions including transcriptional regulation
and chromatin remodeling, and is required for the
development of all lymphoid lineages. The IKZF1
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expression of 1 copy of the gene and haploinsuffi-
ciency, or internal deletion of the gene and expression
of an internally truncated isoform, IK6. This isoform
lacks the N-terminal zinc fingers of IKAROS and can-
not bind DNA, but retains the C-terminal zinc fingers
and can act in a dominant-negative fashion. Existing
data have indicated a role for IKAROS alterations in
tumorigenesis. Mice harboring a dominant-negative
mutation in the Ikzf1 gene develop aggressive T-line-
age lymphoproliferative disease [8], and deletion of
Ikzf1 accelerates leukemogenesis in a murine model
of Ph1 ALL. Recent studies have also shown that in-
herited variations in the IKZF1 gene are associated
with an increased risk of ALL, further supporting
a role for this gene in leukemogenesis [9]. Alterations
of IKZF1 are also associated with poor outcome in
Ph2ALL. The U.S. and Dutch Children’s Oncology
Group have both found that IKZF1 alteration was as-
sociated with a near tripling of the risk of treatment
failure [10,11]. In addition, profiles of serial ALL
samples have identified substantial differences in the
genetic alterations present at diagnosis and relapse
[12]. However, IKZF1 alterations are almost always
preserved fromdiagnosis to relapse, andmay also be ac-
quired as a new lesion at relapse [13,14].
The gene expression profile of poor outcome,
IKZF1-altered B-progenitor ALL is strikingly similar
to that of Ph1 ALL [10,14]. This suggests that
these ‘‘BCR-ABL1-like’’ (Ph-like) cases may harbor
alternative rearrangements or sequence mutations
that activate signaling cascades downstream of
cytokine receptors or tyrosine kinases, and this is
indeed the case.Genetic Characterization of BCR-ABL1-Like,
Ph Negative ALL
Sequencing of tyrosine kinases in high-risk B-pro-
genitor ALL (the COG P9906 cohort) [10] identified
somatic mutations in JAK1, JAK2, and JAK3 in ap-
proximately 10% of cases [15]. The mutations were
most commonly at or near R683 in the pseudokinase
domain of JAK2, but were also found in the kinase
domain of JAK2 and the pseudokinase domain of
JAK1. Strikingly, the V617F mutation commonly
observed in the myeloproliferative disorders has not
been identified in B-progenitor ALL, although the
homolog of JAK2V617F, JAK1V658F, has been iden-
tified [16]. The presence of JAK mutations was associ-
ated with IKZF1 mutations, a BCR-ABL1-like gene
expression profile, and poor outcome. JAK2mutations
(most commonly at R683) are also present in one-
quarter of cases of B-progenitor ALL associated with
Down syndrome [17-19]. The JAK1 and JAK2
mutations observed in ALL are transforming in
vitro, conferring cytokine-independent growth andconstitutive Jak-Stat activation when introduced into
Ba/F3 cells expressing the erythropoietin or thrombo-
poietin receptors [15,18].
The identification of distinct JAK mutations in
myeloproliferative diseases and ALL suggested that
different mutated JAK alleles might interact with dif-
ferent downstream signaling pathways and influence
the disease lineage. Recent studies have shown that
JAK mutations in ALL are associated with chromo-
somal rearrangements resulting in overexpression of
the cytokine receptor CRLF2 (cytokine receptor-like
factor 2, or TSLPR, thymic stromal lymphopoietin
receptor). These rearrangements are either a focal in-
terstitial deletion involving the pseudoautosomal re-
gion 1 (PAR1) of Xp/Yp, or rearrangement of
CRLF2 into the immunoglobulin heavy chain locus
(IGH@-CRLF2) [16]. Both represent a form of pro-
moter/enhancer dysregulation. The PAR1 deletion
results in a novel fusion transcript, P2RY8-CRLF2, in
which the first, noncoding exon of P2RY8 is fused to
the entire coding region ofCRLF2. P2RY8 is a member
of a family of purinergic receptor genes that is
expressed in hematopoietic cells, including leukemic
blasts, and has previously been identified as a rare tar-
get of translocation to SOX5 in lymphoma.
CRLF2 alterations in B-progenitor ALL have been
subsequently confirmed and identified by multiple
groups, including adult ALL [16,20]. CRLF2 is
rearranged in 5% to 7% of B-progenitor childhood
ALL cases. Both alterations result in increased cell
surface expression of CRLF2 by leukemic cells, and
flow cytometric analysis of CRLF2 expression may be
used to detect CRLF2-rearranged cases. Less com-
monly, CRLF2 is rearranged to other, as yet unknown
partner genes or harbors presumed activating muta-
tions, most commonly F232C. A striking observation
is thatCRLF2 alteration,most commonly thePAR1de-
letion, is present in over 50% of ALL associated with
Down syndrome (DS-ALL) [16], in which other chro-
mosomal rearrangements characteristic of childhood
ALL are uncommon. In both DS- and non-DS-ALL,
CRLF2 rearrangement is significantly associated with
the presence of activating Janus kinase mutation.
Over half ofCRLF2-rearranged cases harbor activating
JAK1 or JAK2 mutations, and conversely, nearly all
JAK-mutated cases have CRLF2 rearrangements, sug-
gesting that these lesions together contribute to leuke-
mogenesis. Importantly, in non-DS-ALL, CRLF2
alteration and JAK mutations are associated with the
presence of IKZF1 alterations. Several studies have
observed strong associations between CRLF2/JAK al-
terations and very poor outcome [20], suggesting that
JAK inhibition may be a useful therapeutic approach
in these cases that commonly fail therapy.
Existing data suggest that aberrant CRLF2/JAK
signaling contributes to leukemogenesis. CRLF2
forms a heterodimeric receptor with interleukin-7
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stromal lymphopoietin). TSLP/CRLF2 signaling has
a role in dendritic cell development, T cell responses,
allergic inflammation, and promotes the proliferation
of normal and leukemic B cells. Expression of either
CRLF2 or mutant JAK alleles alone in Ba/F3 cells lack-
ing expression of EpoR/TpoR usually does not result
in transformation [16]. A notable exception is JAK1
V658F, the homolog of JAK2 V617F, which trans-
forms this cell line irrespective of cytokine receptor
coexpression. Prior to the identification of CRLF2
alterations in ALL, JAK mutations in ALL were
shown to transform Ba/F3-EpoR cells to cytokine-
independent growth and result in constitutive Jak-
Stat activation [15,18], suggesting that interaction of
Jak mutants with a cytokine receptor scaffold is
required for transformation. Subsequent studies have
shown that coexpression of JAK mutations and
CRLF2 in Ba/F3 cells is transforming, and that this
transformation is inhibited by either pharmacologic
JAK inhibition or short hairpin RNA–mediated
knockdown of CRLF2 expression [16]. Similarly, stud-
ies using primary murine hematopoietic progenitors
have shown that enforced expression of CRLF2 alone
promotes lymphoid expansion, but this is insufficient
to result in the development of leukemia ([21] and un-
published data). Ongoing studies modeling CRLF2
dysregulation and JAK mutations will be of interest
to determine the role of these alterations in leukemo-
genesis. In addition, such studies will provide preclin-
ical models of ALL that faithfully recapitulate human
leukemia in which to test the efficacy of pharmacologic
JAK inhibitors.Future Directions for Genomic Profiling
in High-Risk ALL
Our understanding of the genetic basis of high-risk
ALL remains incomplete. Almost one-half of CRLF2-
rearranged cases lack an activating JAK mutation, yet
may have a BCR-ABL1-like gene expression profile,
suggesting that additional cooperating or kinase-
activating lesions remain to be identified. Moreover,
many ‘‘BCR-ABL1-like’’ cases lack CRLF2 alterations,
and the genetic alterations driving these leukemias
remain unknown. Similarly, a substantial proportion
of ALL cases remain that lack known cytogenetic alter-
ations and fail therapy, and the frequency of these cases
rises with increasing age. There is a relative lack of
detailed, high-resolution genomic profiling data from
adolescent and adult ALL, which has a markedly infe-
rior outcome to that of childhood ALL. This is a criti-
cal issue and an area of active enquiry. Furthermore,
several high-risk subtypes of leukemia have either
not been studied in detail (eg, ALL with low hypodip-
loidy) or have few structural genetic alterations on
microarray analysis (eg, MLL-rearranged leukemia).Moreover, microarray platforms do not directly
detect structural rearrangements or DNA sequence
alterations.
Ongoing and future genomic profiling studies will
entail analysis of less well-studied cohorts, and the
application of next-generation sequencing approaches
interrogating genetic and epigenetic changes. Next-
generation sequencing of either tumor DNA or
RNA has identified new targets of mutation in acute
myelogenous leukemia (AML), T-lineage ALL, and
lymphoma, and has identified new targets of rearrange-
ment in cancer. Accordingly, preliminary studies in
Ph-likeB-lineageALLhave identified novel rearrange-
ments dysregulatingABL1 and JAK2. It is likely that as
the time and cost requirements of these methods
decline, sequencing-based approaches will assume
greater importance in interrogating cancer genomes
and may supplant array-based methodologies.GENOMICS OF UNRELATED DONOR
HEMATOPOIETIC CELLTRANSPLANTATION
Worldwide clinical experience demonstrates that
HCT from unrelated donors (URDs) can cure both
malignant and nonmalignant blood disorders. Since
its discovery, theHLA system has served as the corner-
stone of transplantation genetics. HLA genes reside
within the major histocompatibility complex (MHC),
the most comprehensively studied multimegabase
region of the human genome. The importance of
MHC resident variation in transplantation, autoim-
munity, and infectious diseases has provided the neces-
sary platform for investigation of the HLA region in
human disease. More than 421 loci are now identified
within the 7.6-Mb extended MHC region, an
estimated 30% of which are involved in immune func-
tion including inflammation, leukocyte maturation,
complement cascade, nonclassical class I, immunoreg-
ulation, stress response, and the immunoglobulin su-
perfamily [22]. Of the 252 expressed genes, over 20%
reside within the class III region, the most gene-dense
region in the genome. The classical HLA genes,HLA-
A, B, C, DR, DQ, and DP encode polypeptides that are
critical in controlling T cell recognition and determin-
ing histocompatibility. Complete and precise URD
matching for 10 alleles at the 5 genetic loci, HLA-A,
B, C, DRB1, DQB1, is associated with lowered risks
of graft rejection, acute and chronic graft-versus-host
disease (aGVHD, cGVHD) and superior survival
compared to HLA mismatching [23]. Despite 10/10
allele matching of URDs, transplant-related complica-
tions are still higher than that observed in sibling
donor transplantation [24].
A hallmark of HLA genes is their extensive degree
of polymorphism and the high degree of nonrandom
association of alleles at 2 or more HLA loci, or linkage
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by the MHC Sequencing Consortium, the HapMap
Project, The Human Genome Project, and The SNP
Consortium has led to a dense map of over 36,000
MHC region single nucleotide polymorphisms
(SNPs) and common haplotypes and important infor-
mation on the organization of MHC region variation.
High LD across the MHC opens the possibility that
some of the over 250 expressed genes with immune
function contribute to posttransplant risks after trans-
plantation. Efforts to identify functional resident
MHC genes may provide new insight into the patho-
genesis of GVHD, and offer new approaches to the
prevention of posttransplant complications [25].GENOMICS OF AML AND
MYELODYSPLASTIC SYNDROME (MDS)
Identifying genetic events that lead to the develop-
ment of AML and MDS will not only provide insight
into the biology of these diseases but also identify
key pathways for therapeutic interventions. There
has been an evolution and revolution in cancer genetics
and genomics over the past 50 years culminating in
novel and robust DNA sequencing technologies and
array-based platforms that have been used to identify
microdeletions, point mutations, amplifications, and
translocations that are associated with these diseases.
In addition to routine cytogenetic analysis and fluores-
cence in situ hybridization (FISH), which have been
used to identify commonly mutated genes in AML
such as FLT3, NPM1, N-ras, CEBPA, and MLL, our
group has explored comparative genomic hybridiza-
tion (CGH) and SNP array-based platforms to help
identify small (\5 Mb) subcytogenetic amplifications
and deletions in the AML genome. These studies
have demonstrated that there are very few recurrent
acquired copy number changes (CNVs) in most
AML genomes, and that these techniquesmay not pro-
vide significantly more information and prognostic
valve than routine cytogenetics and FISH [26]. In
order to overcome the inherent variability of RNA
profiling and the lack of validated technologies for pre-
cisely and reproducibly defining genome-widemethyl-
ation an effort began almost 10 years ago to perform
massive parallel sequencing of AML genomes using
modern platforms in order to take an unbiased view
of both mutations associated with AML and allelic var-
iants that may predispose to the development of both
MDS and AML.
A large percentage of AML genomes are cytoge-
netically normal, and it is this particular group of
AML patients for which optimal therapy has not yet
been defined. In addition, the study of AML genomes
with a array-based high-resolution comparative geno-
mic hybridization approaches has revealed that manyhave no detectable copy number alterations at the
35-kb resolution. From preliminary studies, investiga-
tors determined that cytogenetically normal (diploid)
genomes contain many fewer mutations than cancer
genomes that are highly aneuploid. The likelihood of
identifying mutations that might be pathogenetically
relevant was improved by first focusing on these less
complex cancer genomes. In addition, a number of
mutations that have been now confirmed in hemato-
logic malignancies have been seen in solid tumor
malignancies (RAS, ALK).
In order to take a comprehensive and unbiased look
at the AML and MDS genomes, next-generation se-
quencing has been applied, despite its significant cost
andmanpower requirements. A collaborative effort be-
tweenmultiple departments atWashingtonUniversity
School of Medicine and the Washington University
Genome Center has completed the sequencing of
over 100 AML andMDS genomes [27]. The technolo-
gies developed for the sequencing of AML genomes
have been extended to other diseases including breast
cancer, multiple myeloma, lung cancer, glioblastoma
multiforme and genitourinary malignancies [28].
Finally, access to germline DNA (skin biopsies or buc-
cal rinses) has been absolutely essential and has allowed
us to attribute sequence changes in AML genomes to
either polymorphisms or somatic mutations.
The projected cost of using traditional Sanger-
based sequencing for human genomes would be
approximately $90 million per genome, but with the
advent of next-generation technology, the cost has
already fallen to between $50,000 and $100,000 per
cancer-germline pair. The expense is justified in light
of the fact that humans have 3-4 million sequence
variations and hundreds of copy number variations.
Because of the large number of variations, sequencing
of both tumor and matched normal tissue needs to be
performed. Because most somatic mutations will be
heterozygous, both alleles must be sequenced at every
position in the genome to obtain adequate coverage for
mutation discovery, whereas only 6-fold coverage (ie,
18 billion base pairs of sequence for a 3 billion base-
paired genome) is required to solve a genome’s pri-
mary structure; at least 4 times that or 25-fold coverage
(72 billion bases pairs of sequence) is required to
achieve adequate diploid coverage for comprehensive
mutation discovery.
Currently, a shotgun sequencing method using
‘‘paired end reads’’ on massively parallel sequencing
devices is the method of choice in most genome cen-
ters. Libraries of DNA fragments from AML and
MDS tumor specimens can now be made with very
limited amounts of DNA (as little as 100 ng), which
is critical because sample abundance is very limiting
for many tumors. Our initial work on sequencing can-
cer genomes focused on unidirectional short-fragment
reads of 30-35 base pairs in length. Because of these
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ped back to the referenced genome and longer reads,
100 base pairs in length, are now being read bidirec-
tionally in so-called paired end reads. This dramati-
cally reduces the cost and increases the overall
efficiency of the sequencing reactions. In addition,
paired end reads now dramatically increases our ability
to identify structural variants such as deletions,
amplifications, translocations, insertions-deletions
(INDELs), and inversions. As the size of the fragments
in these libraries increases, there is a dramatically
increased chance of identifying translocations, which
was almost impossible using libraries made from
shorter DNA fragments.
Exon-capture methods are being developed and
are being used widely. There are advantages, including
large numbers of patients that could potentially be
screened and the deep read counts for each captured
exon ensuring high sensitivity for mutation discovery.
Disadvantages are that these approaches are biased
toward predefined regions of the genome, and the effi-
ciency of capture method is still far from perfect. This
must be considered still a work in progress.
The time now required to complete the sequenc-
ing of both tumor and germline DNA for simple dip-
loid AML genomes is less than 1 week, and the cost is
approximately $50,000/$100,000. This represents a
10- to 100-fold reduction in cost and time required
to complete compared to the first genome sequenced.
The first genome sequenced was chosen specifi-
cally in a patient with de novo AML and the most com-
mon FAB classification of AML (M1). The patient was
\60 years and had no exposure to chemotherapy and
had no history of MDS. This patient had normal
cytogenetics and no obvious microdeletions, amplifi-
cations, or INDELs using high-resolution and
array-based technologies. Finally, this patient was
also chosen because she eventually relapsed, which
would allow us to identify relapse-specific mutations,
which we have already completed. Surprisingly, in
this first genome, we found only 10 nonsynonymous
mutations within coding regions. By performing
deep read counts of variant allele frequency for each
mutation, we were able to establish that all of these
nonsynonymous mutations were present in virtually
all tumor cells. Only 4 of these mutations were found
in the 187 additional AML genomes that were tested,
strongly suggesting that they are indeed important
for pathogenesis [27]. A second AML genome was
sequenced [29]. There were only 12 mutations in
coding regions and 54 mutations that were not in cod-
ing regions but did fall in highly conserved or regula-
tory regions of the genome.
The challenge is to sift through all of the noise in
order to identify which mutations are recurrent and
which of the recurrent mutations are driver mutations.
To develop preclinical and animal models to test thebiology of these mutations in biological systems will
also be challenging and may require the development
of completely novel in vitro and in vivo models. The
final frontier will be to correlate the presence of the
specific mutations with outcomes. Of note, in the sec-
ond AML genome sequenced, we identified recurrent
mutations, IDH1 and IDH2, which occur quite fre-
quently in glioblastoma and were present in 8% to
9% of de novo AML patients. We also showed, which
was confirmed by other groups, that these mutations
were associated with a poor outcome.
MDS genomes are complex compared to de novo
AML, and current studies are starting to document
mutations. Additional or recurrent mutations that
have important predictive impact on outcomes in pa-
tients with AML and MDS will also be identified in
these studies. Identification of relapse-specific muta-
tions that occur not only after standard antileukemic
chemotherapy, but also after less aggressive therapies
such as hypomethylating therapies and after maximally
aggressive therapies such as allogeneic stem cell trans-
plantation, will be of clinical importance.ACKNOWLEDGMENTS
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